Skip to Main Content

Paper Details

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Clin Cancer Res
2
2023
Author NameAffiliation
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Qingyi WeiThe University of Texas MD Anderson Cancer Center
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
  • 1 - 5

Datasets

Release 1.2